BUSINESS
MSD Japan Suffers 7% Sales Dip on Repeated Keytruda Re-Pricing, Urges Policy Rethink
April 21, 2021
Stellar sales performances are at times a mixed bag of good and bad for drug makers operating in Japan. This holds so true for US Merck’s I/O star Keytruda (pembrolizumab), which was hit by two…

LATEST

April 21, 2021
After a series of first decisions made around Japan’s cost-effectiveness assessment (CEA) scheme, EFPIA issued a statement on April 20 that sorted out issues identified with experiences of its member firms and recommended corrective measures…
April 21, 2021
The Japan Association of Vaccine Industries on April 20 urged the government to establish control tower functions to promote public-private-academic cooperation and collaborations between companies and global partners in the infectious disease arena. It also…
April 21, 2021
Japan on April 20 officially announced new NHI prices based on cost-effectiveness assessments (CEAs) for Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) and GlaxoSmithKline’s COPD drug Trelegy (fluticasone furoate + umeclidinium + vilanterol), which will take…
By Takashi Ohama

The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…

By Yoshinori Sagehashi

Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…

Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Philip Carrigan

After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA